Alendronate Sodium in the Management of Osteoporosis

Figures & data

Table 1 Fracture risk in postmenopausal women with a prevalent vertebral fracture*

Fracture type	Placebo (%)	Alendronate (%)	Fracture risk (95% CI)
Morphometric ≥1	145 (15)	78 (8)	0.53 (0.41–0.68)
Morphometric ≥−2	47 (4.9)	5 (0.5)	0.10 (0.05–0.22)
Clinical vertebral	50 (5.0)	23 (2.3)	0.45 (0.27–0.72)
Any clinical	183 (18.2)	139 (13.6)	0.72 (0.58–0.90)
Any non-vertebral	148 (14.7)	122 (11.9)	0.80 (0.63–1.01)
Hip	22 (2.2)	11 (1.1)	0.49 (0.23–0.99)
Wrist	41 (4.1)	22 (2.2)	0.52 (0.31–0.87)
Height loss (mm)	9.3	6.1	p<0.001

* Note: Black et al 1996.

Abbreviations: CI, confidence interval.

Table 2 Fracture risk in postmenopausal women without a prevalent vertebral fracture*

Fracture type	Placebo (%)	Alendronate (%)	Fracture risk (95% CI)
Morphometric ≥1	78 (3.8)	43 (2.1)	0.56 (0.39–0.80)
Morphometric ≥2	10 (0.5)	4 (0.2)	0.40 (0.13–1.24)
Clinical vertebral**
Any clinical	312 (14.1)	272 (12.3)	0.86 (0.73–1.01)
Any non-vertebral	294 (13.3)	261 (11.8)	0.88 (0.74–1.04)
Hip	24 (1.1)	19 (0.9)	0.79 (0.43–1.44)
Wrist	70 (3.2)	83 (3.7)	1.19 (0.87–1.64)
Height loss (mm)	8.5	7.0	p<0.001

* Note: Cummings et al 1998

** Clinical vertebral fractures included in “any clinical” fractures.

Abbreviations: CI, confidence interval.

Table 3 Fracture risk in osteoporotic postmenopausal cohort*

Fracture type	Vertebral Fx Arm RR (95% CI)	Clinical Fx Arm (T < −2.5) RR (95% CI)	Osteoporotic cohort RR (95% CI)
Morphometric ≥1	0.53 (0.41–0.68)	0.51 (0.31–0.84)	0.52 (0.42–0.66)
Morphometric ≥2	0.10 (0.05–0.22)	0.40 (0.08–1.95)	0.13 (0.07–0.25)
Clinical vertebral	0.46 (0.28–0.75)	0.84 (0.38–1.83)	0.55 (0.36–0.82)
Any clinical	0.74 (0.59–0.92)	0.64 (0.50–0.82)	0.70 (0.59–0.82)
Any non-vertebral	0.81 (0.64–1.03)	0.65 (0.50–0.83)	0.73 (0.61–0.87)
Hip	0.49 (0.23–0.99)	0.44 (0.18–0.97)	0.47 (0.26–0.79)
Wrist	0.52 (0.31–0.87)	0.88 (0.55–1.40)	0.70 (0.49–0.90)

* Note: Black et al 2000.

Abbreviations: CI, confidence interval; Fx, fracture; RR, relative risk.

BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet19963481535418950879

 PubMed Web of Science ®Google Scholar

CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fracturesJAMA19982802077829875874

 PubMed Web of Science ®Google Scholar

BlackDMThompsonDEBauerDCFracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trialJ Clin Endocrinol Metab20008541182411095442

 PubMed Web of Science ®Google Scholar